

Herwig H Kollaritsch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/666659/publications.pdf>

Version: 2024-02-01

89
papers

2,906
citations

134610

34
h-index

206121

51
g-index

99
all docs

99
docs citations

99
times ranked

3394
citing authors

#	ARTICLE	IF	CITATIONS
1	Chapter 14: Prevention: vaccines and immunoglobulins. Tick-borne Encephalitis - the Book, 2022, , .	0.0	0
2	Tick-Borne Encephalitis Vaccines. , 2021, , 159-168.		0
3	Antibody seroprevalence and rate of asymptomatic infections with SARS-CoV-2 in Austrian hospital personnel. BMC Infectious Diseases, 2021, 21, 915.	1.3	4
4	Vaccination in Multiple Sclerosis: Friend or Foe?. Frontiers in Immunology, 2019, 10, 1883.	2.2	70
5	Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study. Vaccine, 2019, 37, 2529-2531.	1.7	12
6	Recommended/Required Travel Vaccines. , 2019, , 101-124.		3
7	Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Scientific Reports, 2018, 8, 9825.	1.6	72
8	Tickborne Encephalitis Vaccines. , 2018, , 1080-1094.e5.		4
9	Tick-Borne Encephalitis Vaccines. , 2017, , 137-145.		1
10	Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study. Vaccine, 2016, 34, 4579-4585.	1.7	22
11	Genetic Variation of Bordetella pertussis in Austria. PLoS ONE, 2015, 10, e0132623.	1.1	17
12	Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis. Vaccine, 2015, 33, 3600-3604.	1.7	34
13	Characteristics of invasive pneumococcal disease in hospitalized children in Austria. European Journal of Pediatrics, 2014, 173, 469-476.	1.3	8
14	Treatment of Traveler's Diarrhea. Current Treatment Options in Infectious Diseases, 2014, 6, 74-80.	0.8	0
15	Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis. Vaccine, 2014, 32, 5696-5702.	1.7	37
16	A Novel Multivalent OspA Vaccine against Lyme Borreliosis Is Safe and Immunogenic in an Adult Population Previously Infected with Borrelia burgdorferi Sensu Lato. Vaccine Journal, 2014, 21, 1490-1499.	3.2	36
17	Sustained low hospitalization rates after four years of rotavirus mass vaccination in Austria. Vaccine, 2013, 31, 2686-2691.	1.7	65
18	Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination. Vaccine, 2013, 31, 1293-1297.	1.7	43

#	ARTICLE	IF	CITATIONS
19	Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 680-689.	4.6	84
20	Tick-Borne Encephalitis (TBE) and Hepatitis B Nonresponders Feature Different Immunologic Mechanisms in Response to TBE and Influenza Vaccination with Involvement of Regulatory T and B Cells and IL-10. <i>Journal of Immunology</i> , 2013, 191, 2426-2436.	0.4	48
21	Gender-specific distribution of mefloquine in the blood following the administration of therapeutic doses. <i>Malaria Journal</i> , 2013, 12, 443.	0.8	10
22	Principles of Immunization. , 2013, , 67-76.		6
23	Special Adult Travel Vaccines. , 2013, , 101-123.		2
24	Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose priming. <i>Vaccine</i> , 2012, 30, 6127-6135.	1.7	23
25	Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. <i>Vaccine</i> , 2012, 30, 4543-4551.	1.7	15
26	Vaccines and vaccination against tick-borne encephalitis. <i>Expert Review of Vaccines</i> , 2012, 11, 1103-1119.	2.0	77
27	Traveler's Diarrhea. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 691-706.	1.9	40
28	Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51. <i>Vaccine</i> , 2011, 29, 2607-2612.	1.7	51
29	Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. <i>Vaccine</i> , 2011, 29, 2791-2796.	1.7	105
30	The current perspective on tick-borne encephalitis awareness and prevention in six Central and Eastern European countries: Report from a meeting of experts convened to discuss TBE in their region. <i>Vaccine</i> , 2011, 29, 4556-4564.	1.7	46
31	Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines. <i>Vaccine</i> , 2011, 29, 5130-5136.	1.7	13
32	Universal Mass Vaccination Against Rotavirus Gastroenteritis. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 319-323.	1.1	106
33	A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®. <i>Vaccine</i> , 2010, 28, 1209-1216.	1.7	104
34	IC51 Japanese Encephalitis vaccine. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 921-931.	1.4	33
35	Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees. <i>Vaccine</i> , 2009, 27, 197-204.	1.7	25
36	Booster vaccinations against tick-borne encephalitis: 6 Years follow-up indicates long-term protection. <i>Vaccine</i> , 2009, 27, 7027-7030.	1.7	36

#	ARTICLE	IF	CITATIONS
37	Pharmacodynamic interaction between monodesbutyl-benflumetol and artemisinin as well as proguanil in Plasmodium falciparum in vitro. Wiener Klinische Wochenschrift, 2008, 120, 90-94.	1.0	2
38	Japanese encephalitis and vaccines: past and future prospects. Wiener Klinische Wochenschrift, 2008, 120, 15-19.	1.0	16
39	Interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum in vitro. Wiener Klinische Wochenschrift, 2008, 120, 85-89.	1.0	6
40	Pretravel Consultation: Rapid Dipstick Test as a Decision Guidance for the Application of Tetanus Booster Vaccinations. Journal of Travel Medicine, 2008, 15, 437-441.	1.4	23
41	Vaccination with Dukoral [®] against travelers'™ diarrhea (ETEC) and cholera. Expert Review of Vaccines, 2008, 7, 561-567.	2.0	74
42	Seroprotection 4 years following booster vaccination against tick-borne encephalitis. International Journal of Medical Microbiology, 2008, 298, 305-308.	1.5	5
43	After a tick bite in a tick-borne encephalitis virus endemic area: Current positions about post-exposure treatment. Vaccine, 2008, 26, 863-868.	1.7	45
44	Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine, 2008, 26, 6151-6156.	1.7	46
45	Principles of Immunization. , 2008, , 75-84.		1
46	Impact of a Pertussis Booster Vaccination Program in Adolescents and Adults on the Epidemiology of Pertussis in Austria. Pediatric Infectious Disease Journal, 2007, 26, 806-810.	1.1	36
47	Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine, 2007, 25, 927-931.	1.7	50
48	Antibody persistence following booster vaccination against tick-borne encephalitis: 3-Year post-booster follow-up. Vaccine, 2007, 25, 5097-5101.	1.7	45
49	The Risk of Acquiring Hepatitis A and B Among Travelers in Selected Eastern and Southern Europe and Non-European Mediterranean Countries: Review and Consensus Statement on Hepatitis A and B Vaccination. Journal of Travel Medicine, 2007, 14, 181-187.	1.4	24
50	Epidemiology of Travel-Associated and Autochthonous Hepatitis A in Austrian Children, 1998 to 2005. Journal of Travel Medicine, 2007, 14, 248-253.	1.4	9
51	Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum. Wiener Klinische Wochenschrift, 2007, 119, 60-66.	1.0	7
52	Spezifische pharmakodynamische Interaktion zwischen Atovaquon und Retinol bei Plasmodium falciparum. Wiener Klinische Wochenschrift, 2007, 119, 45-52.	1.0	4
53	Synergistic interaction between monodesbutyl-benflumetol and retinol in Plasmodium falciparum. Wiener Klinische Wochenschrift, 2007, 119, 53-59.	1.0	3
54	Persistence of antibodies after vaccination against tick-borne encephalitis. International Journal of Medical Microbiology, 2006, 296, 202-207.	1.5	41

#	ARTICLE	IF	CITATIONS
55	Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. <i>Vaccine</i> , 2006, 24, 2781-2789.	1.7	116
56	Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: Estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. <i>Vaccine</i> , 2006, 24, 5960-5965.	1.7	24
57	Active hospital-based surveillance of rotavirus diarrhea in Austrian children, period 1997 to 2003. <i>Wiener Klinische Wochenschrift</i> , 2006, 118, 280-285.	1.0	20
58	Vaccines against traveler's diarrhoea and rotavirus disease – a review. <i>Wiener Klinische Wochenschrift</i> , 2006, 118, 2-8.	1.0	13
59	In vitro interaction between artemisinin and chloroquine as well as desbutyl-benflumetol in <i>Plasmodium vivax</i> . <i>Wiener Klinische Wochenschrift</i> , 2006, 118, 62-69.	1.0	5
60	Pharmacodynamic interaction between atovaquone and other antimalarial compounds against <i>Plasmodium falciparum</i> in vitro. <i>Wiener Klinische Wochenschrift</i> , 2006, 118, 70-76.	1.0	6
61	Drug sensitivity of <i>Plasmodium falciparum</i> along the Thai-Myanmar border using the new field-deployable HRP2 in vitro assay. <i>Wiener Klinische Wochenschrift</i> , 2005, 117, 35-38.	1.0	4
62	Synergism of desbutyl-benflumetol and retinol against <i>Plasmodium falciparum</i> in vitro. <i>Wiener Klinische Wochenschrift</i> , 2005, 117, 39-44.	1.0	6
63	In vitro activity of artemisinin alone and in combination with retinol against <i>Plasmodium falciparum</i> . <i>Wiener Klinische Wochenschrift</i> , 2005, 117, 45-48.	1.0	12
64	Simple Histidine-Rich Protein 2 Double-Site Sandwich Enzyme-Linked Immunosorbent Assay for Use in Malaria Drug Sensitivity Testing. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3575-3577.	1.4	132
65	Prospective surveillance of incidence, serotypes and antimicrobial susceptibility of invasive <i>Streptococcus pneumoniae</i> among hospitalized children in Austria. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 826-831.	1.3	26
66	Screening for Mutations Related to Atovaquone/Proguanil Resistance in Treatment Failures and Other Imported Isolates of <i>Plasmodium falciparum</i> in Europe. <i>Journal of Infectious Diseases</i> , 2004, 190, 1541-1546.	1.9	73
67	A randomized, open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults. <i>Clinical Therapeutics</i> , 2004, 26, 1084-1091.	1.1	21
68	A HISTIDINE-RICH PROTEIN 2-BASED MALARIA DRUG SENSITIVITY ASSAY FOR FIELD USE. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004, 71, 711-714.	0.6	49
69	A histidine-rich protein 2-based malaria drug sensitivity assay for field use. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004, 71, 711-4.	0.6	32
70	Comparative study on the in vitro activity of lumefantrine and desbutyl-benflumetol in fresh isolates of <i>Plasmodium vivax</i> from Thailand. <i>Wiener Klinische Wochenschrift</i> , 2004, 116 Suppl 4, 47-52.	1.0	9
71	Humoral immune response against proteophosphoglycan surface antigens of <i>Entamoeba histolytica</i> elicited by immunization with synthetic mimotope peptides. <i>FEMS Immunology and Medical Microbiology</i> , 2003, 37, 179-183.	2.7	12
72	Pharmacodynamic Interaction of Doxycycline and Artemisinin in <i>Plasmodium falciparum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 262-264.	1.4	15

#	ARTICLE	IF	CITATIONS
73	Drug Prophylaxis for Travelers' Diarrhea. <i>Clinical Infectious Diseases</i> , 2002, 34, 628-633.	2.9	49
74	Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. <i>Acta Tropica</i> , 2002, 81, 167-173.	0.9	49
75	<i>Plasmodium falciparum</i> : effect of anti-malarial drugs on the production and secretion characteristics of histidine-rich protein II. <i>Experimental Parasitology</i> , 2002, 102, 157-163.	0.5	49
76	Antigenicity and immunogenicity of phage library-selected peptide mimics of the major surface proteophosphoglycan antigens of <i>Entamoeba histolytica</i> . <i>Parasite Immunology</i> , 2002, 24, 321-328.	0.7	17
77	Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. <i>Vaccine</i> , 2001, 19, 2055-2060.	1.7	94
78	Effects of Miltefosine and Other Alkylphosphocholines on Human Intestinal Parasite <i>Entamoeba histolytica</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1505-1510.	1.4	80
79	A New Approach for Chemotherapy Against <i>Entamoeba histolytica</i> . <i>Archives of Medical Research</i> , 2000, 31, S6-S7.	1.5	3
80	Isolation of Phage Mimotopes Mimicking a Protective Epitope of GPI-Linked Proteophosphoglycan Antigens of <i>Entamoeba histolytica</i> . <i>Archives of Medical Research</i> , 2000, 31, S309-S310.	1.5	0
81	Seroprevalence of diphtheria immunity among injured adults in Austria. <i>Vaccine</i> , 2000, 19, 1061-1067.	1.7	18
82	Double-Blind, Randomized, Placebo Controlled Pilot Study Evaluating Efficacy and Reactogenicity of an Oral ETEC B-Subunit-Inactivated Whole Cell Vaccine against Travelers' Diarrhea (Preliminary) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>		
83	Interference of Antibody Production to Hepatitis B Surface Antigen in a Combination Hepatitis A/Hepatitis B Vaccine. <i>Journal of Infectious Diseases</i> , 1999, 180, 2018-2022.	1.9	39
84	Chloroquine resistance of <i>Plasmodium falciparum</i> : a biological advantage?. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1995, 89, 90-91.	0.7	22
85	Inverse correlation of sensitivity in vitro of <i>Plasmodium falciparum</i> to chloroquine and mefloquine in Ghana. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1994, 88, 443-444.	0.7	14
86	Parasite density of <i>Plasmodium falciparum</i> malaria in Ghanaian schoolchildren: evidence for influence of sex hormones?. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1994, 88, 73-74.	0.7	41
87	<i>Plasmodium falciparum</i> : susceptibility in vitro and in vivo to chloroquine and sulfadoxine-pyrimethamine in Ghanaian schoolchildren. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1994, 88, 440-442.	0.7	32
88	Albendazole is highly effective against cutaneous larva migrans but not against <i>Giardia</i> infection: results of an open pilot trial in travellers returning from the tropics. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1993, 87, 689.	0.7	37
89	Chapter 14: Prevention " Vaccines + Immunoglobulins. <i>Tick-borne Encephalitis - the Book</i> , 0, , .	0.0	1